PBHPrestige Consumer Healthcare Inc.
Pharmaceutical Preparations
- Revenue
- $1.1B
- 4.3% YoY
- Operating margin
- 28.4%
- 4.0% YoY
- EBITDA
- $341M
- 7.2% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.7×
- $905M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear135% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear61% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear14% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | 4.3% |
| Operating income | $330M | −$22M | $342M | $337M | $309M | 8.1% |
| Net income | $205M | −$82M | $209M | $215M | $190M | 11% |
| Operating cash flow | $260M | $230M | $249M | $252M | $258M | 2.4% |
| Capex | $10M | $8M | $10M | $8M | $11M | 36% |
| Stock-based comp | $9M | $12M | $14M | $11M | $11M | 2.9% |
| Buybacks | $0 | $50M | $25M | $52M | $156M | 203% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | $6M | $826K | 134 | 70 |
| FY2025 | $6M | $8M | 195 | 114 |
| FY2024 | $6M | $10M | 165 | 100 |
| FY2023 | $6M | $10M | 142 | 88 |
| FY2022 | $6M | $10M | 120 | 100 |